GEN Exclusives

More »

GEN News Highlights

More »
Oct 22, 2008

MDRNA Gains Patents Covering Technology to Enhance Profile of RNAi Drugs

  • MDRNA obtained intellectual property related to non-nucleotide chemistry technology from RiboTask. Unlocked nucleic acid (UNA) will permit MDRNA to stabilize and provide drug-like properties to RISC and dicer length siRNAs.

    “Unlocked Nucleic Acid, an acyclic ribonucleoside analog, increases the breadth of MDRNA's technology platform by providing additional, novel RNA chemistries,” according to Michael Templin, Ph.D., vp of drug discovery and pharmaceutical development. “The research we have conducted in our laboratories suggests that the addition of UNA increases siRNA stability, reduces off-target activity, and improves gene silencing, characteristics that are widely accepted as key to improved siRNA safety and efficacy.”

    RiboTask is leveraging the UNA technology in diagnostic and reagent applications. In UNAs, the bond between C2' and C3' atoms is broken. This change in sugar structure makes the nucleoside analog flexible. This in turn reduces the binding affinity between two strands of an siRNA molecule.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?